The National Institutes of Health filed a formal Federal Register consultation on November 16, 2026, seeking comments by January 6, 2027, on expanding data and safety monitoring to all NIH-supported clinical research. The proposal would bring more university studies into a risk-based oversight framework, making its scope and approval requirements consequential for investigators and research offices.
New filing follows NIH’s November 2 draft
Federal Register document 2026-23300 was filed at 8:45 a.m. on November 16 and is scheduled for publication on November 17. It contains the draft policy and a request for information, with a written-comment deadline of January 6. The notice is dated November 10 and signed by NIH Principal Deputy Director Matthew J. Memoli.
The filing follows the agency’s November 2 release of NOT-OD-27-006. The newly filed formal notice advances that consultation; it does not adopt the draft or make its proposed requirements effective. NIH is asking whether the approach appropriately protects participants and data integrity, and what guidance would help institutions implement it without unnecessary burden.
Monitoring would extend beyond clinical trials
The central change is coverage. NIH proposes expanding expectations established for clinical trials to all NIH-supported clinical research. The draft’s definition includes patient-oriented research, epidemiological and behavioral studies, and outcomes and health services research. NIH says almost two thirds of its clinical research portfolio consists of studies that are not clinical trials, whose data can support later trial research.
Risk assessment would shape each data and safety monitoring plan. The draft treats risk broadly: participant safety, privacy and confidentiality; data quality and integrity; study complexity and systems; NIH financial stewardship; and other significant concerns, including data security. Assessment could be revisited as a study progresses, rather than treated solely as a decision made at startup.
Under the proposed text, plans would identify critical risks and explain the monitoring methods, evaluation criteria, responses to problems, and documentation. They would also describe reasons for temporary suspension or premature discontinuation and how monitoring reports would be communicated and reviewed. The awarding NIH Institute, Center or Office, collectively termed an ICO, would approve the initial plan before human subject activities begin.
Independent oversight would turn on study risk
NIH describes another change as removing the requirement for Data and Safety Monitoring Boards for all phase 3 or multi-site clinical trials. The replacement would be a study-specific assessment of whether independent monitoring is needed. An independent monitor could be an individual, committee or board, with expertise, responsibilities and independence defined in the plan.
The draft retains investigator monitoring in every study. Independent monitoring would supplement that work where risk warrants it, and the ICO would have to identify its reason for requiring it in writing. NIH says independence can add expertise, reduce bias and protect against conflicts of interest or undue influence.
Risk-proportionate monitoring itself has a long history. The June 10, 1998 NIH policy already linked monitoring to a trial’s risks, size and complexity. The current proposal would broaden the research covered and recast the independent-monitoring decision around each study’s risk assessment.
Earlier sector and campus analysis flags wider reach
In analysis published on November 9, before the Federal Register filing, CITI Program highlighted the implications for institutions conducting research beyond clinical trials. It described responsibilities for developing plans, assessing risks, responding to findings and updating oversight, and suggested involving research administration, human research protections, clinical operations and compliance teams in reviewing the draft.
Harvard Medical School’s existing research-compliance alert likewise draws attention to broader clinical-research coverage, risk-tailored NIH-approved plans and removal of the blanket board requirement. It identifies the January 6 comment deadline and the proposed six-month interval between final policy publication and the application dates covered. These are existing assessments of the draft, rather than new reactions to the November 16 filing.
University workflows would have to connect distinct roles
If finalized as drafted, the policy would make plan approval a study-startup consideration for covered non-trial research as well as trials. For research offices, the practical implication would be connecting application preparation, illustrated in CASRAI’s NIH human-subjects section example, with the proposed monitoring-plan review and approval process before human subject activities start.
The draft leaves the recipient institution responsible for research conduct, even when investigators carry out specified duties. NIH ICO oversight would remain distinct from monitoring performed by investigators, sponsors or independent monitors. Investigators would also have to follow applicable Institutional Review Board requirements. NIH encourages a single monitoring plan that serves NIH, the IRB and other applicable regulators, consistent with Good Clinical Practice.
Oversight would continue throughout the study. The proposed provisions call for at least annual review of routine monitoring reports by people with appropriate expertise, arrangements for expedited reporting when risks trigger escalation, and plan amendments when protocols or risks change. Monitoring costs, including staff time and independent-monitor compensation, could be allowable within study budgets under the draft.
Comments due January 6, with implementation tied to a final policy
The formal request seeks views on calibrating oversight to risk, deciding when independent monitoring adds value, and determining what data-quality issues should be monitored. NIH also invites input on supporting tools, templates, example plans and guidance for different study designs. Responses are voluntary and may be anonymous; NIH warns that submissions may later be made public without redaction.
The immediate opportunity is to comment through the process linked in NIH’s notice by January 6, 2027. Under the draft timetable, the policy would apply to applications submitted on or after six months following publication of a final policy. Its proposed scope lists competing award applications, competitive revisions, contract proposals and other funding agreements, as well as IRB-approved intramural projects. That application timetable is conditional on finalization.
Sources
- Federal Register public inspection: Draft Policy Update to the NIH Policy for Data and Safety Monitoring, document 2026-23300, checked 2026-11-16.
- NIH: NOT-OD-27-006, Draft Policy Update to the NIH Policy for Data and Safety Monitoring, checked 2026-11-16.
- NIH: NIH Policy for Data and Safety Monitoring, June 10, 1998, checked 2026-11-16.
- CITI Program: NIH Seeks Public Comment on Draft Update to Data and Safety Monitoring Policy, checked 2026-11-16.
- Harvard Medical School Academic and Research Integrity: Alerts and News, checked 2026-11-16.







